IOBT

IO Biotech Inc

IOBT, USA

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.

https://www.iobiotech.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IOBT
stock
IOBT

IO Biotech (NASDAQ: IOBT) 5-year data show 60-month OS, >53-month responses Stock Titan

Read more →
IOBT
stock
IOBT

What drives IOBT stock price - Stock Price Forecasts & Low Cost Capital Trading earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$2.4633

Analyst Picks

Strong Buy

2

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

59.34

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-919.65 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-20.97 %

Low 2%

High 10%

Debt to Equity

-

Very Low

42.86

Low 1

High 0.3

Investors

* Institutions hold a combined 33.77% of the total shares of IO Biotech Inc

1.

Vivo Capital, LLC

(9.3706%)

since

2025/06/30

2.

HBM Healthcare Investments AG Ord

(5.9873%)

since

2025/06/30

3.

Novo A/S

(5.0917%)

since

2025/06/30

4.

Marshall Wace Asset Management Ltd

(3.1956%)

since

2025/06/30

5.

Partner Fund Management LP

(2.9934%)

since

2025/06/30

6.

Bank of America Corp

(2.4515%)

since

2025/06/30

8.

Morgan Stanley - Brokerage Accounts

(0.9922%)

since

2025/06/30

9.

LANDSCAPE CAPITAL MANAGEMENT,LLC

(0.5273%)

since

2025/06/30

10.

Dauntless Investment Group, LLC

(0.4924%)

since

2025/06/30

11.

Soleus Capital Management, L.P.

(0.2925%)

since

2025/06/30

12.

Renaissance Technologies Corp

(0.2114%)

since

2025/06/30

13.

Sectoral Asset Management Inc

(0.1786%)

since

2025/06/30

14.

Protea Sectoral Biotech Opps IF USD Acc

(0.1388%)

since

2025/05/31

15.

Bridgeway Capital Management, LLC

(0.1138%)

since

2025/06/30

16.

Bridgeway Ultra-Small Company Market

(0.1138%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.0506%)

since

2025/06/30

18.

Fidelity Nasdaq Composite Index

(0.0506%)

since

2025/07/31

19.

XTX Topco Ltd

(0.0443%)

since

2025/06/30

20.

Citadel Advisors Llc

(0.0438%)

since

2025/06/30

21.

Jane Street Group LLC

(0.0394%)

since

2025/06/30

22.

Goss Wealth Management LLC

(0.0368%)

since

2025/06/30

23.

UBS Group AG

(0.0201%)

since

2025/06/30

24.

Cubist Systematic Strategies, LLC

(0.0199%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2125

Latest Release

Date

2025-09-30

EPS Actual

-0.2498

EPS Estimate

-0.345

EPS Difference

0.0952

Surprise Percent

27.5942%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.